Pharmaceutical Business review

Cyprotex names new chief commercial officer

Mr Bury joins Cyprotex from Shanghai ChemPartner, where he was director of business development and responsible for growing the company’s European preclinical services business.

He previously held the position of business development director at Scottish Biomedical, where he managed the company’s global business development team and had worldwide responsibility for revenue generation from drug discovery projects.

Anthony Baxter, CEO of Cyprotex, said: “I am delighted to announce the appointment of Simon to the role of chief commercial officer. His knowledge and experience of our industry, coupled with his extensive sales and marketing expertise, will undoubtedly strengthen our relationships with existing partners as well as developing new relationships with potential clients.”